The trial investigates whether a medication called Orforglipron, taken as a tablet once daily by mouth, can help reduce the number of incontinence episodes experienced each week. Orforglipron belongs to a class of medications known as GLP-1 receptor agonists, which work by mimicking a natural hormone in the body that helps regulate appetite and body weight. By potentially helping participants lose weight, this medication may also reduce pressure on the bladder and improve incontinence symptoms. Some participants will receive placebo instead of the active medication.

The study aims to determine if Orforglipron is more effective than placebo in decreasing the frequency of urinary leakage episodes. Participants will take one tablet daily throughout the treatment period, and their incontinence episodes will be monitored and recorded. This is a Phase 3 trial sponsored by Eli Lilly, designed to evaluate both the effectiveness and safety of the medication in this specific patient population.

The purpose of the study is to understand how this treatment affects the balance of blood clotting and breakdown in the body, known as the hemostatic balance. This is important because changes in this balance can affect the risk of blood clots. The study will involve postmenopausal women who will receive the treatment for a period of three months. During this time, researchers will monitor changes in blood clotting and breakdown processes to see if the treatment has any significant effects.

Participants in the study will receive the treatment at least three times a week. The study aims to compare the effects of the treatment on women with and without a history of venous thromboembolism (VTE), which is a condition where blood clots form in the veins. By the end of the study, researchers hope to gather valuable information on how local vaginal estrogen treatment influences blood clotting and breakdown in postmenopausal women.

Participants in the study will receive injections of the stem cell treatment or a placebo into the urethral sphincter, which is a muscle that helps control the release of urine. The main goal is to see if the treatment can reduce the amount of urine leakage, as measured by a pad test, and to monitor any side effects. The study will also assess the safety of the treatment over time. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

The study will take place over several years, with participants being monitored for changes in their urinary symptoms and any potential side effects. The researchers aim to determine if the stem cell treatment can improve bladder function and reduce symptoms of urinary incontinence. This trial represents an important step in finding new ways to help patients manage urinary incontinence after prostate surgery.

The purpose of the study is to evaluate how well these treatments work in reducing the number of wet days, which are days when accidental leakage occurs. Participants will be randomly assigned to receive either solifenacin, mirabegron, a combination of both, or a placebo. The study will last for a total of 18 weeks, with the main treatment period being 12 weeks. During this time, the number of wet days will be monitored to see how the treatments are working. The study will also look at other factors, such as changes in the severity of incontinence and the amount of urine the bladder can hold.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study aims to provide valuable information on the best treatment options for children with overactive bladder and daytime urinary incontinence, potentially improving their quality of life. Participants will be closely monitored to ensure their safety and well-being during the trial.

The purpose of the study is to determine if stopping these medications suddenly or gradually affects the likelihood of the incontinence returning. Participants in the study will either stop taking their medication all at once or gradually reduce their dosage over time. The study will monitor the recurrence of incontinence over a period of up to 12 months. Additionally, the study will look for any symptoms that might occur when the medication is stopped.

Participants will be children who have been successfully treated for urinary incontinence with solifenacin and/or mirabegron. The study will track their progress and any changes in their condition after the medication is withdrawn. The goal is to better understand how to manage the discontinuation of these treatments in children who have achieved continence.